Bertran-Mostazo, AndreaPutriute, GabrieléÁlvarez-Berbel, IreneBusquets i Viñas, Ma. AntoniaGaldeano Cantador, CarlosEspargaró Colomé, AlbaSabaté Lagunas, Raimon2024-10-212024-10-212024-03-042073-4409https://hdl.handle.net/2445/215920<p>Proximity-induced pharmacology (PIP) for amyloid-related diseases is a cutting-edge</p><p>approach to treating conditions such as Alzheimer’s disease and other forms of dementia. By bringing</p><p>small molecules close to amyloid-related proteins, these molecules can induce a plethora of effects</p><p>that can break down pathogenic proteins and reduce the buildup of plaques. One of the most</p><p>promising aspects of this drug discovery modality is that it can be used to target specific types of</p><p>amyloid proteins, such as the beta-amyloid protein that is commonly associated with Alzheimer’s</p><p>disease. This level of specificity could allow for more targeted and effective treatments. With ongoing</p><p>research and development, it is hoped that these treatments can be refined and optimized to provide</p><p>even greater benefits to patients. As our understanding of the underlying mechanisms of these</p><p>diseases continues to grow, proximity-induced pharmacology treatments may become an increasingly</p><p>important tool in the fight against dementia and other related conditions.</p>1 p.application/pdfengcc-by (c) Bertran-Mostazo, A. et al., 2024http://creativecommons.org/licenses/by/4.0/Malalties neurodegenerativesAmiloïdosiDisseny de medicamentsNeurodegenerative DiseasesAmyloidosisDrug designinfo:eu-repo/semantics/article7469152024-10-21info:eu-repo/semantics/openAccess